MedTrace Logo

Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

NCT05847049 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2023-05-06

No results posted yet for this study

Summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Conditions

  • Central Serous Chorioretinopathy

Interventions

OTHER

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Sponsors & Collaborators

  • Dar El Oyoun Hospital

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2023-03-25
Completion
2023-04-06

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05847049 on ClinicalTrials.gov